The role of polymerase theta inhibition in pancreatic cancers with BRCA1/BRCA2 and non-BRCA HR defects and possibly defects in other repair pathways could be the logical step for investigation in future trials. Here, BRCA1 is linked to familial pancreatic carcinoma.